CN117736134A
(en)
*
|
2012-01-12 |
2024-03-22 |
耶鲁大学 |
Compounds and methods for enhancing degradation of target proteins and other polypeptides by E3 ubiquitin ligases
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
EP3708170A1
(en)
|
2014-05-05 |
2020-09-16 |
BioVentures, LLC |
Compositions and methods for inhibiting antiapoptotic bcl-2 proteins as anti-aging agents
|
AU2015292710A1
(en)
|
2014-07-22 |
2017-02-16 |
Bioventures, Llc. |
Compositions and methods for selectively depleting senescent cells
|
US10071164B2
(en)
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
WO2016118666A1
(en)
|
2015-01-20 |
2016-07-28 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of the androgen receptor
|
US20170327469A1
(en)
|
2015-01-20 |
2017-11-16 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
GB201504314D0
(en)
*
|
2015-03-13 |
2015-04-29 |
Univ Dundee |
Small molecules
|
BR112017019751A2
(en)
|
2015-03-18 |
2018-05-29 |
Arvinas Inc |
bifunctional compound, pharmaceutical composition, and methods for treating or preventing a disease or disorder, and for degrading a target protein in a cell
|
US20180147202A1
(en)
|
2015-06-05 |
2018-05-31 |
Arvinas, Inc. |
TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE
|
US10772962B2
(en)
|
2015-08-19 |
2020-09-15 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
WO2017079267A1
(en)
|
2015-11-02 |
2017-05-11 |
Yale University |
Proteolysis targeting chimera compounds and methods of preparing and using same
|
KR102447884B1
(en)
|
2016-04-21 |
2022-09-27 |
바이오벤처스, 엘엘씨 |
Compounds inducing degradation of anti-apoptotic BCL-2 family proteins and uses thereof
|
GB201610156D0
(en)
|
2016-06-10 |
2016-07-27 |
Otsuka Pharma Co Ltd |
Cliptac compositions
|
AU2017313085A1
(en)
|
2016-08-19 |
2019-03-14 |
Beigene Switzerland Gmbh |
Use of a combination comprising a Btk inhibitor for treating cancers
|
CA3087528C
(en)
|
2016-09-15 |
2024-01-30 |
Arvinas, Inc. |
Indole derivatives as estrogen receptor degraders
|
JP6899993B2
(en)
*
|
2016-10-04 |
2021-07-07 |
国立医薬品食品衛生研究所長 |
Heterocyclic compound
|
KR102173463B1
(en)
|
2016-10-11 |
2020-11-04 |
아비나스 오퍼레이션스, 인코포레이티드 |
Compounds and methods for the targeted degradation of androgen receptor
|
US11458123B2
(en)
|
2016-11-01 |
2022-10-04 |
Arvinas Operations, Inc. |
Tau-protein targeting PROTACs and associated methods of use
|
KR20190082989A
(en)
|
2016-12-01 |
2019-07-10 |
아비나스 오퍼레이션스, 인코포레이티드 |
Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor release
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
AU2017382406A1
(en)
|
2016-12-23 |
2019-04-18 |
Arvinas Operations, Inc. |
EGFR proteolysis targeting chimeric molecules and associated methods of use
|
MX2019007649A
(en)
|
2016-12-23 |
2019-09-10 |
Arvinas Operations Inc |
Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides.
|
EP3559006A4
(en)
|
2016-12-23 |
2021-03-03 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
CN117551089A
(en)
|
2017-01-26 |
2024-02-13 |
阿尔维纳斯运营股份有限公司 |
Estrogen receptor proteolytic modulators and related methods of use
|
CA3066518A1
(en)
|
2017-06-26 |
2019-01-03 |
Beigene, Ltd. |
Immunotherapy for hepatocellular carcinoma
|
US11358948B2
(en)
|
2017-09-22 |
2022-06-14 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
IL307995A
(en)
|
2017-09-22 |
2023-12-01 |
Kymera Therapeutics Inc |
Protein degraders and uses thereof
|
WO2019099926A1
(en)
|
2017-11-17 |
2019-05-23 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
|
WO2019108795A1
(en)
|
2017-11-29 |
2019-06-06 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
|
WO2019114770A1
(en)
*
|
2017-12-13 |
2019-06-20 |
上海科技大学 |
Alk protein degradation agent and anti-tumor application thereof
|
US10519152B2
(en)
|
2017-12-21 |
2019-12-31 |
Astrazeneca Ab |
Compounds and their use in treating cancer
|
MX2020006812A
(en)
|
2017-12-26 |
2020-11-06 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof.
|
EP3737666A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
US11512080B2
(en)
|
2018-01-12 |
2022-11-29 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
US11220515B2
(en)
|
2018-01-26 |
2022-01-11 |
Yale University |
Imide-based modulators of proteolysis and associated methods of use
|
CN112218859A
(en)
|
2018-04-04 |
2021-01-12 |
阿尔维纳斯运营股份有限公司 |
Modulators of proteolysis and related methods of use
|
US11667621B2
(en)
|
2018-06-11 |
2023-06-06 |
Stevens Institute Of Technology |
Antiestrogen compounds
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
JPWO2020027225A1
(en)
|
2018-07-31 |
2021-11-11 |
ファイメクス株式会社 |
Heterocyclic compound
|
JP7297053B2
(en)
|
2018-08-20 |
2023-06-23 |
アルビナス・オペレーションズ・インコーポレイテッド |
Alpha-Synuclein Protein-Targeted Proteolysis Targeting Chimeric (PROTAC) Compounds with E3 Ubiquitin Ligase Binding Activity to Treat Neurodegenerative Diseases
|
US11352350B2
(en)
|
2018-11-30 |
2022-06-07 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
US20220160890A1
(en)
|
2019-02-21 |
2022-05-26 |
Locki Therapeutics Limited |
Survival-targeting chimeric (surtac) molecules
|
KR20220006139A
(en)
|
2019-04-05 |
2022-01-14 |
카이메라 쎄라퓨틱스 인코포레이티드 |
STAT degradation agents and uses thereof
|
JP2022532342A
(en)
|
2019-05-14 |
2022-07-14 |
ニューベイション・バイオ・インコーポレイテッド |
Anti-cancer nuclear hormone receptor targeting compound
|
KR20220032063A
(en)
|
2019-06-28 |
2022-03-15 |
카이메라 쎄라퓨틱스 인코포레이티드 |
IRAK disintegrants and uses thereof
|
US11912699B2
(en)
|
2019-07-17 |
2024-02-27 |
Arvinas Operations, Inc. |
Tau-protein targeting compounds and associated
|
WO2021097046A1
(en)
|
2019-11-13 |
2021-05-20 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
US11591332B2
(en)
|
2019-12-17 |
2023-02-28 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
IL293917A
(en)
|
2019-12-17 |
2022-08-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
TW202136240A
(en)
|
2019-12-19 |
2021-10-01 |
美商亞文納營運公司 |
Compounds and methods for the targeted degradation of androgen receptor
|
CA3162502A1
(en)
|
2019-12-23 |
2021-07-01 |
Yi Zhang |
Smarca degraders and uses thereof
|
EP4121043A1
(en)
|
2020-03-19 |
2023-01-25 |
Kymera Therapeutics, Inc. |
Mdm2 degraders and uses thereof
|
TW202210483A
(en)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Crystalline forms of irak degraders
|
CN112094307A
(en)
*
|
2020-09-28 |
2020-12-18 |
深圳市术理科技有限公司 |
Compound for target ubiquitination degradation of ER alpha protein and application thereof
|
WO2022120355A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead degraders and uses thereof
|
IL306010A
(en)
|
2021-03-23 |
2023-11-01 |
Nuvation Bio Inc |
Anti-cancer nuclear hormone receptor-targeting compounds
|
WO2023076161A1
(en)
|
2021-10-25 |
2023-05-04 |
Kymera Therapeutics, Inc. |
Tyk2 degraders and uses thereof
|
WO2024050016A1
(en)
|
2022-08-31 |
2024-03-07 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|
WO2024054591A1
(en)
|
2022-09-07 |
2024-03-14 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
|
WO2024064358A1
(en)
|
2022-09-23 |
2024-03-28 |
Ifm Due, Inc. |
Compounds and compositions for treating conditions associated with sting activity
|